Philip James Wealth Mangement LLC Sells 2,883 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Philip James Wealth Mangement LLC reduced its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 5.8% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 46,646 shares of the biopharmaceutical company's stock after selling 2,883 shares during the period. Philip James Wealth Mangement LLC's holdings in Gilead Sciences were worth $5,227,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Annis Gardner Whiting Capital Advisors LLC raised its position in Gilead Sciences by 158.8% in the fourth quarter. Annis Gardner Whiting Capital Advisors LLC now owns 352 shares of the biopharmaceutical company's stock worth $33,000 after purchasing an additional 216 shares in the last quarter. Whipplewood Advisors LLC acquired a new position in Gilead Sciences during the fourth quarter worth $35,000. Synergy Investment Management LLC bought a new position in shares of Gilead Sciences during the fourth quarter valued at $40,000. Lee Danner & Bass Inc. acquired a new stake in shares of Gilead Sciences in the 4th quarter valued at $41,000. Finally, Investment Research & Advisory Group Inc. grew its holdings in shares of Gilead Sciences by 33.3% in the 1st quarter. Investment Research & Advisory Group Inc. now owns 400 shares of the biopharmaceutical company's stock worth $45,000 after purchasing an additional 100 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences Stock Up 1.6%

Shares of Gilead Sciences stock opened at $107.62 on Friday. The company has a market capitalization of $133.87 billion, a P/E ratio of 22.66, a price-to-earnings-growth ratio of 0.69 and a beta of 0.29. The company has a debt-to-equity ratio of 1.16, a current ratio of 1.37 and a quick ratio of 1.23. The business has a 50-day moving average of $106.27 and a two-hundred day moving average of $103.15. Gilead Sciences, Inc. has a 1 year low of $66.01 and a 1 year high of $119.96.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.77 by $0.04. The business had revenue of $6.67 billion during the quarter, compared to analysts' expectations of $6.77 billion. Gilead Sciences had a return on equity of 51.93% and a net margin of 20.76%. Gilead Sciences's revenue for the quarter was down .3% compared to the same quarter last year. During the same period in the prior year, the business earned ($1.32) EPS. As a group, equities analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, June 27th. Investors of record on Friday, June 13th will be issued a dividend of $0.79 per share. The ex-dividend date of this dividend is Friday, June 13th. This represents a $3.16 annualized dividend and a yield of 2.94%. Gilead Sciences's payout ratio is presently 66.53%.

Insider Buying and Selling at Gilead Sciences

In other news, insider Johanna Mercier sold 28,000 shares of the stock in a transaction that occurred on Thursday, May 22nd. The stock was sold at an average price of $107.52, for a total transaction of $3,010,560.00. Following the transaction, the insider now owns 121,152 shares in the company, valued at approximately $13,026,263.04. This trade represents a 18.77% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Andrew D. Dickinson sold 2,500 shares of the business's stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $110.17, for a total transaction of $275,425.00. Following the completion of the sale, the chief financial officer now directly owns 165,110 shares of the company's stock, valued at $18,190,168.70. This represents a 1.49% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 48,500 shares of company stock worth $5,236,245 over the last ninety days. 0.27% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several brokerages recently issued reports on GILD. Morgan Stanley lifted their price target on shares of Gilead Sciences from $130.00 to $135.00 and gave the company an "overweight" rating in a report on Friday, April 25th. Oppenheimer reduced their target price on Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating on the stock in a report on Friday, April 25th. Bank of America increased their price target on Gilead Sciences from $116.00 to $126.00 and gave the stock a "buy" rating in a research report on Wednesday, March 5th. JPMorgan Chase & Co. upped their price target on shares of Gilead Sciences from $120.00 to $130.00 and gave the stock an "overweight" rating in a research report on Thursday, March 27th. Finally, Cantor Fitzgerald initiated coverage on shares of Gilead Sciences in a research report on Tuesday, April 22nd. They issued an "overweight" rating and a $125.00 price objective for the company. Nine analysts have rated the stock with a hold rating, fifteen have issued a buy rating and three have given a strong buy rating to the company's stock. According to data from MarketBeat.com, Gilead Sciences has an average rating of "Moderate Buy" and an average target price of $110.55.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.